He aha ka GenScript 27% Nā hōʻailona ulu H1 no nā kaulahao hoʻolako peptide

Pane wikiwiki

Translate GenScript's 27% H1 growth into procurement tactics: lead-time pressure points, analytical window locking, and specification-based sourcing.

Nā hōʻailona ulu macro vs. Nā ʻoiaʻiʻo o ka mana CDMO

ʻO ka piʻi ʻana o ka noi honua no nā peptides maʻamau ke hana hou nei i ka hoʻokaʻawale ʻana i ka mana hana hana. Ua hoʻolālā nā paepae synthesis kiʻekiʻe i nā huli hoʻohiwahiwa no nā peptides linear maʻamau (malalo 20 nā amino acids me ka maʻemaʻe maʻamau), ka hāʻawi ʻana i nā manawa huli e like me ka catalog me ka wikiwiki 5 i 7 nā lā ʻoihana. Eia naʻe, hana kēia automation kiʻekiʻe i kahi ʻāina hoʻopuka bi-modal ma waena o ka ʻO ka mākeke peptide ulu ʻo GenScript H1.

Kūlana / Nā Kaʻina Linear (<20 aa, ≤85% Maʻemaʻe) ► Nā Laina Automated High-Throughput (5–7 La Hana Hana)

Paʻakikī / Nā Kaʻina Kuʻuna (≥95% Maʻemaʻe, Hoʻololi ʻia) ► Hoʻomaʻemaʻe hoʻomākaukau kūikawā & QA (3–6 pule)

Ke hoʻomau nei nā mega-CDMO i ke kapikala a me ka hoʻokomo ʻana o ka hale ma luna o nā ʻaelike kiʻekiʻe kiʻekiʻe, nā kaʻina hana maʻamau me nā koi hoʻomaʻemaʻe ikaika a i ʻole nā ​​​​hoʻololi kemika maʻamau maʻamau e komo i nā laina hoʻomaʻemaʻe manual a semi-automated..

Ki Takeaway: ʻO ka ulu ʻana o ka loaʻa kālā macro kiʻekiʻe ma waena o nā mea lawelawe kiʻekiʻe e hōʻike ana i ka mālama ʻana i ka laina laina. ʻOiai e neʻe wikiwiki ana nā peptides screening ma waho o ka papa, nā kaʻina maʻamau me ka maʻemaʻe kiʻekiʻe (≥95–98%), hoʻololi paʻakikī, a i ʻole nā ​​koi o ka lumi hoʻomaʻemaʻe sterile e ʻike i nā mea hoʻopaʻa hoʻonohonoho disproportionate.


ʻO nā Bottlenecks Huna e hoʻonui ana i nā manawa alakaʻi i ka Chain Supply Peptide

ʻAʻole i kaupalena ʻia ka manawa alakaʻi no nā peptides maʻamau e ka hui pū ʻana o ka peptide synthesis solid-phase. (SPSS) hoʻokahi wale nō. aka, Hoʻonui ʻia ka papa hana i ka wā o ka hoʻoili ʻana ma hope o ka synthesis: chromatography wai hana kiʻekiʻe (RP-HPLC), hoʻololi kūʻē, nā pōʻai lyophilization, a hoʻokuʻu i ka hōʻoia maikaʻi (QA).

1. Nā Paepae Maʻemaʻe a me Chromatographic Recycling

Hoʻonui i kahi kikoʻī peptide mai 85% ʻO ka maʻemaʻe o ka noiʻi ʻana i ka ≥95% a i ʻole ≥98% no nā haʻawina hoʻonaʻauao IND e hoʻokumu i ke kelepona a i ʻole preclinical e hoʻololi nui i ka hana hoʻoikaika.:

  • 85% Maemae: Hoʻomaʻemaʻe hoʻokahi-pass RP-HPLC maʻamau. ʻO ka huli ʻana o ka hana maʻamau: 2 i 3 pule pule.
  • ≥95% a ≥98% Maʻemaʻe: Pono ka hōʻiliʻili haʻihaʻi-nui, kahi ʻaʻahu kiʻekiʻe, a me ka hoʻolike hou ʻana o ke kolamu. Inā loaʻa nā kaʻina holoi holoi a i ʻole diastereomers, hāʻule nui ka hua, e koi ana i ka unahi kalaiwa SPPS mua. ʻO ka huli ʻana o ka hana maʻamau: 3 i 5 pule pule.

2. ʻO ke Kaʻina Hydrophobicity a me ka Hoʻohui

Nā kaʻina peptide i loaʻa i kahi ʻāpana kiʻekiʻe (>40%) o nā waikawa amino hydrophobic (Valine, Isoleucine, Leucine, Phenylalanine, Tryptophan) e hana i ka intermolecular beta-sheet aggregates i ka wā synthesis a me ka hoʻomaʻemaʻe. Ka noiʻi i paʻi ʻia ma Hui Kimia ʻAmelika (ACS) nā haʻawina hoʻohui peptide e hōʻike ana i ka hoʻololi ʻana o ka hydrophobicity i ka paʻa ʻana o ka chromatographic a me ka solubility i loko o nā ʻāpana kelepona wai..

No nā mea kūʻai, Hōʻike nā kaʻina hydrophobic i kahi pilikia o ka hana pālua: nā hua hoʻoheheʻe crude haʻahaʻa a me ka hoʻoponopono hoʻomaʻemaʻe lōʻihi, hoʻohui pinepine 1 i 3 nā pule i ka papa kuhikuhi hoʻouna.

3. Kūʻai Kūʻē: Trifluoroacetate (TFA) i ka Acetate

Hoʻohana ka cleavage SPPS maʻamau i ka waikawa trifluoroacetic, e waiho ana i ke koena TFA counterions i hoʻopaʻa ʻia i nā koena amino acid kumu (ʻO Lysine, Arginine, Histidine) a me ka N-terminus. No ka mea, hōʻike ʻo TFA i ka cytotoxicity nui i nā hoʻokolohua cell a me nā haʻawina vivo, Hōʻike pinepine nā mea kūʻai biopharma i nā ʻano paʻakai acetate a i ʻole ammonium.

ʻO ka hoʻololi ʻana i nā paʻakai TFA i acetate e pono ai ka chromatography hoʻololi ion-exchange lua a i ʻole ka hoʻomaloʻo maloʻo hou ʻana mai nā hopena acetic acid dilute.. Hoʻohui kēia kaʻina hana hou 3 i 5 nā lā ʻoihana i ke ala hoʻokuʻu analytical.


I ka manawa e laka ai i ka Windows Analytical: He Alakaʻi Kūʻai Kūʻai

No ka pale ʻana i ka lohi o ka papahana, Pono nā hui kūʻai a me nā hui loiloi e hoʻonohonoho i nā protocol hoʻāʻo me nā pae hana mea kūʻai aku. ʻO ke kali ʻana a hiki i ka hoʻohui ʻia ʻana o kahi pūʻulu ma mua o ka wehewehe ʻana i nā pae hoʻāʻo hoʻokuʻu ʻana ke kumu nui o ka hakakā ʻana.

Ka Papahana Analytical Lock Milestone Palapala Pahu & Nā mea hāʻawi Hoʻemi ʻia ka pilikia o ka hana
Pre-Synthesis (T-emi 4 Nā pule pule) Hiki i ke kaʻina laka, maʻemaʻe pahuhopu (≥95% vs. ≥98%), a me ke ano paakai (TFA vs. Acetate). Manaʻo loea mua, manaʻo hoʻohua maʻemaʻe, hōʻoia hoʻohālikelike ʻana i ka solvent. Hoʻohuihui Peptide ʻO ka hāʻule ʻana o ka synthesis ma nā kaʻina paʻakikī/hydrophobic; hoʻololi kikoʻī kikoʻī i waena o ka holo.
I ka hana (T-emi 2 Nā pule pule) Hoʻopau i nā ʻāpana ʻano analytical LC-MS a me nā lula hoʻohui HPLC. Ua ʻae ʻia ka lōʻihi hawewe ʻike UV (214 nm / 280 nm), paepae hoʻohui kiʻekiʻe. ʻO nā kuʻikahi e pili ana i nā ʻano helu maʻemaʻe i ka wā o ka loiloi CoA hope loa.
Hoʻokuʻu hoʻāʻo (T-emi 1 Pule) E hōʻoia i ka bioburden, endotoxin (<0.01 EU/µg), a me nā protocol hoʻāʻo ʻana i ka makū/wai. Palapala Hōʻoiaʻiʻo o ka ʻIkepili (KoA) me nā chromatograms HPLC maka a me MS spectra. ʻO ka hōʻole ʻana i ka hoʻouna ʻana ma muli o ka contamination endotoxin a i ʻole ka ʻike maka.

No ke kōkua: E koi mau i nā mea kūʻai aku e hoʻolako i nā chromatograms HPLC maka a me Mass Spectrometry (MS) spectra e pili ana i ka palapala hōʻoia (KoA). ʻO ka ʻike maopopo i nā baseline hoʻohui e hōʻoia i ka helu pololei ʻana o nā haumia peptidic liʻiliʻi ma mua o ke komo ʻana o nā mea i kāu kaila hana noiʻi..


Pehea e hoʻololi ai nā koho kikoʻī i kāu kumu hoʻolālā

Ke kūkulu ʻana i kahi kūpono hoʻolālā kūʻai peptide maʻamau pono e loiloi i ka hopena o nā koho kikoʻī i ke koho ʻana i nā mea kūʻai aku. ʻO ka hilinaʻi wale ʻana ma kahi mega-CDMO hoʻokahi no nā peptides screening maʻalahi a me nā kūkulu hoʻololi kiʻekiʻe-spec hiki ke hana i nā bottlenecks pipeline i manaʻo ʻole ʻia..

Palapala Hōʻikeʻike Peptide

Linear maʻamau / Huli wikiwiki

  • Ka lōʻihi <20 aa
  • Hoʻomaʻemaʻe Nānā (>85%) ʻO Mega-CDMO ʻokoʻa ʻo Tier-1 (Kiʻekiʻe Loaʻa / Kūlana)

Maemae Kiekie (≥95-98%) / Paʻa ʻole

  • Hydrophobic / Hoʻololi ʻia
  • Paakai Acetate / ʻO Endotoxin Free Agile Specialized Platform (Papa MOL Changes 100 Maʻemaʻe)

Hoʻohālikelike i nā kikoʻī i ka mea kūʻai aku

  1. Nā Hale Waihona Puke & Linear Peptides maʻalahi: ʻOi aku ka maikaʻi o nā mea hoʻolako mega ma ka hana ʻana i nā puke kiʻekiʻe o ka pōkole, nā kaʻina maʻamau kahi i hoʻohuli ʻia ka wikiwiki ka metric mua.
  2. Nā Hoʻololi Paʻakikī & Kiekie-Maemae-Pili: No nā kūkulu kaulahao lōʻihi, peptides pōʻai, phosphorylation nui-pae, a i ʻole nā ​​ʻakika amino kūlohelohe ʻole, lilo ka agility kūikawā i mea koʻikoʻi. Ka launa pū ʻana me ka hāʻawi ʻana i nā paepae maʻalahi nā lawelawe hana peptide synthesis maʻamau hōʻoia i ka kūkākūkā ʻenehana hoʻolaʻa a me ke kamaʻilio pololei me nā loea kemika organik.
  3. Paʻa ʻole & Nā Koina Haʻahaʻa-Endotoxin: Ke koi nei ka moʻomeheu cell a me ka noiʻi in vivo i nā mana kaiapuni i ka wā synthesis, ka hoomaemae ana, a me ka paʻi ʻana. Ke hoʻohana nei i nā mea hoʻolako i lako ʻO nā Peptides Synthetic me Papa 100 nā lako lumi hoʻomaʻemaʻe sterile hoʻopau i ka ʻōpala a me ka hopena endotoxin ma ke kumu.

Puke Paʻi Kūʻai: 4 Nā ʻanuʻu noʻonoʻo e hoʻopau i ka pilikia o kāu Pipeline Peptide

No ka hoʻopau ʻana i ka hoʻonui ʻana i ka manawa alakaʻi a hōʻoia i ka hoʻomau o ka hoʻolako ʻana i kāu R&Nā polokalamu D, apono i keia mau hana kuai eha:

ʻanuʻu 1: E hoʻokumu i ka Rolling 8-a-12-Week Lead-Time Buffers

E neʻe aku i kahi-kauoha no nā moho peptide koʻikoʻi. E kūkulu i nā wānana i kēlā me kēia makahiki me nā mea kūʻai mua a me nā mea kūʻai lua. ʻO ka hoʻokumu ʻana i kahi laina hoʻopaʻa no nā hoʻolaha noiʻi e hiki mai ana e hoʻopaʻa i ka hiki ʻana o ka reactor synthesis i nā pule ma mua o ka pau ʻana o ka hoʻopaʻa ʻana..

ʻanuʻu 2: E hoʻokō i kahi papa hana ʻelua-Sourcing Strategy

Hōʻalo i ka mea kūʻai hoʻokahi laka. E mālama i nā pilina me ʻelua mau mea hoʻolako lawelawe kūpono:

  • Mea kūʻai mua: Mea hāʻawi kiʻekiʻe no ka hana maʻamau, ʻO nā peptides kānana haʻahaʻa haʻahaʻa.
  • lua / Mea kūʻai kūikawā: Mea hoʻolako Agile me hiki ke hoʻololi peptide kiʻekiʻe no nā kaʻina hydrophobic paʻakikī, nā peptides i hoʻopaʻa ʻia, a i ʻole ka hoʻomaʻemaʻe kiʻekiʻe (milligrams i kilokani).

ʻanuʻu 3: Hoʻokaʻawale i ka nānā mua ʻana mai ka Hope Counterion Exchange

I ka loiloi ʻana i ka peptide i ka hōʻoia mua ʻana, kauoha i nā peptides ma ke ʻano paʻakai TFA maʻamau ma >85% a i ʻole >90% maʻemaʻe e hōʻemi i nā manawa alakaʻi. E mālama i ka hoʻololi ʻana o ka TFA-to-acetate a me ≥98% ka hoʻomaʻemaʻe hoʻomaʻemaʻe wale nō no ka loiloi alakaʻi a me nā moho preclinical..

ʻanuʻu 4: Hoʻoponopono i nā papa inoa hoʻokuʻu CoA i ʻāpono ʻia

E wehewehe i ka ʻae ʻana ma mua o ke kau ʻana i nā kauoha. E hōʻoia i nā kauoha a kāu mea kūʻai aku:

  • Hōʻoia hoʻomaʻemaʻe RP-HPLC ʻelua hawewe (214 nm a 280 nm).
  • Electrospray Ionization LC-MS (ESI-LC-MS) hōʻoia ʻike molecular weight.
  • Hoʻokomo ʻia ka ʻikepili maka piha i ka palapala CoA hope loa.

Nīnau pinepine (FAQ)

He aha ka manawa alakaʻi maʻamau no ka synthesis peptide maʻamau?

Nā peptides laina maʻamau ma lalo 20 ʻO nā waikawa amino ma 85-90% ka maʻemaʻe e pono ai 2 i 3 pule pule. Eia naʻe, kiʻekiʻe maʻemaʻe pae (≥95% i 98%), hoʻololi paʻakikī, hydrophobic sequences, a i ʻole nā ​​hoʻololi counterion (TFA i ka acetate) hoʻonui i nā manawa alakaʻi i 3 i 6 nā pule ma muli o ka hiki ke kūʻai aku.

Pehea e hana maʻamau peptide hoʻomaʻemaʻe hoʻololi kikoʻī pili i ka hua synthesis?

ʻO ka loaʻa ʻana o ≥98% maʻemaʻe e koi pinepine i ka kahiki chromatographic peaks i ka wā RP-HPLC, e hoemi ana i ka huina waiwai i loaa mai 30% i 50% hoohalikeia me kahi 85% holo kino. Pono nā mea kūʻai aku e hoʻonui i ka nui o ka hopena paʻa paʻa mua e hāʻawi i ka nui hope loa, ke hoʻonui nei i ke kumukūʻai maka a me ka manawa hana. Hana ʻia ʻo Peptide

No ke aha e pono ai ka wehe ʻana i ka counterion TFA no ka hoʻāʻo ʻana i ke kelepona?

Trifluoroacetate (TFA) he mea ʻawaʻawa ia o ka hoʻokaʻawale ʻana i ka hana paʻa. Hiki i nā haʻahaʻa haʻahaʻa o ke koena TFA ke hoʻololi i ka permeability membrane cell, keʻakeʻa i ka ulu ʻana o nā cell, a e hoʻoulu i nā mea ʻawaʻawa maikaʻi ʻole i nā hopena bioassays hana. Manaʻo ikaika ʻia ka Acetate a i ʻole formate exchange no nā moʻomeheu cell āpau a me ka noiʻi vivo.


Nā ʻanuʻu aʻe no nā mea hoʻoholo i ke kūʻai ʻana i ka Peptide

ʻO ka hoʻokele ʻana i ka hiki ke hoʻololi i ka mākeke peptide honua e koi i ka hoʻolālā proactive, hoʻokele kikoʻī koʻikoʻi, a me nā hui kūʻai agile. Ke kaulike nei i nā mea hoʻolako kiʻekiʻe me nā mea kūikawā, ʻO nā hoa hana e pili ana i ka maikaʻi e pale i kāu R&D ka palena manawa e kū'ē i ka hoʻopaʻapaʻa hoʻolako ʻole.

Inā hoʻokele kāu hui noiʻi i ka synthesis sequence paʻakikī, nā palena endotoxin koʻikoʻi, a i ʻole nā ​​pilikia hoʻololi maʻamau, e loiloi i kāu mau koho me kahi hoa agile i kūkulu ʻia no ka pololei ʻenehana. E ʻimi pehea MOL Changes hāʻawi i ka synthesis maʻamau maʻemaʻe kiʻekiʻe, Papa 100 sterile cleanroom control, a me nā palapala CoA maopopo i hoʻohālikelike ʻia i nā pahuhopu noiʻi biopharma.

Xiaoxia Chen

Xiaoxia Chen

Laau Laau Hou R&D ʻenehana Kaʻike kumu: Loaʻa ka pahuhopu, pilina hana-hana (SAR) kālailai, peptide-lāʻau conjugates (Nā PDC), a me ka hoʻomohala ʻana i nā peptides anti-kahiko a me ka metabolic.

Pilikino: Ua alakaʻi ʻo Xiaoxia Chen i ka ʻike mua ʻana a me ka noiʻi preclinical no kekahi mau lāʻau peptide metabolic a me ka tumor-targeted.. ʻAʻole wale ʻo ia i mākaukau i ka nānā ʻana i nā hale waihona puke peptide, akā akamai nō hoʻi i ka hoʻohana ʻana i ka biology computational kōkua AI no ka hoʻolālā ʻana o ka de novo peptide sequence.. I kēia manawa, ke alakaʻi nei ʻo ia i kahi hui i hoʻolaʻa ʻia i ka noiʻi hohonu a me ka hoʻomohala ʻana o nā agonists multifunctional hanauna hou (like me pālua- a i ʻole nā ​​peptides hoʻohaʻahaʻa momona ʻekolu) a me nā peptides hoʻoponopono hou i ke kino.

ʻIke ʻia & Nā alakaʻi hoʻoponopono
Nānā ʻia e: Ka poe akamai kumuhana
Kaʻana like i kēia ʻatikala
Home Huli Whatsapp Nā lawelawe Huahana